Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Approves Vivus’ Obesity Drug, Recommends Against Use In High-Risk Heart Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

A Risk Evaluation and Mitigation Strategy for Qsymia includes prescriber education about the risk of birth defects and limits dispensing to specially certified pharmacies

You may also be interested in...



Can Vivus Get Away Without Outcomes Study Of Obesity Drug Qsymia?

Fixed-dose combination of phentermine and topiramate is FDA-approved for chronic, long-term use, but the average duration in the real world is only about 2.1 months, which is reassuring for Qsymia’s cardiovascular safety, according to a new retrospective claims study.

Women’s Intuition: What Approval Of Sprout’s Addyi Means For Sponsors

Filing for a drug with questionable risk-benefit profile was saved by a trial protocol redesign, strict safety labeling for a narrow indication, a REMS, patient mobilization and plenty of postmarketing studies. Trial period echoes FDA’s approach with a similar sector of lifestyle drug: obesity.

To Market Qsymia, Vivus Takes On Additional Debt

Sales of the weight-loss drug haven’t been brisk, but Vivus can fortify its balance sheet with up to $110 million in debt. Analysts say it could raise more soon, provided it gains a regulatory victory.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel